Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

Presentation ACC 2024

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

Presenter: Javed Butler

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Todd Neale

July 17, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

Shelley Wood

November 30, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

Advertisement

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

CMS Announces Negotiated Medicare Prices for First 10 Drugs

TCTMD’s Top 10 Most Popular Stories for April 2024

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

What’s Going to Be Hot at ACC 2024

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

TCTMD’s Top 10 Most Popular Stories for November 2022

What’s Going to Be Hot at ESC 2022?

TCTMD’s Top 10 Most Popular Stories for March 2022

TCTMD’s Top 10 Most Popular Stories for February 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

TCTMD’s Top 10 Most Popular Stories for November 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content